Vytorin defenders funded by drugmakers

Remember how the American Heart Association rushed to the defense of Vytorin after the results of the Enhance study were released last week? The group issued a statement saying that the study showed the drug to be as safe as the competition, and patients shouldn't rush to judgment.

Well, now several news outlets are pointing out that the association gets almost $2 million annually from Merck and Schering-Plough, which make Vytorin; that AHA president Dan Jones has been a Merck consultant; and that among the $2 million in contributions was a $350,000 sponsorship of a cholesterol page on the association's website--a page that was difficult to distinguish from AHA's other content. In response, the association revamped that web page to make its sponsorship more evident.

Too late, though, for the House Energy and Commerce Committee, which now says it will probe the relationship between AHA and Merck/Schering-Plough. The committee also plans to look into links between the companies and the American College of Cardiology, which also issued a statement last week telling patients not to stop taking Vytorin without consulting a doctor. For the record, both groups say their drug company funding had nothing to do with their public statements.

- read the article from the New York Times
- see this Pharmalot item
- see this release from the House committee on its Vytorin probe
- read the AHA's statement

Related Articles:
Vytorin, Zetia scrips plummet. Report
Heart docs back Vytorin. Report
Congress promises Vytorin hearings. Report
Merck, Schering's Vytorin fails trial. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.